Datapack - Pharmaprojects Pharma R&D Annual Review 2017

  • ID: 4238978
  • Report
  • 17 Pages
  • BMT
1 of 3
Stay Informed on Industry R&D Trends and Perform Your Own in-Depth Analysis

Stay informed on industry R&D trends and perform your own in-depth analysis. This datapack presents the supporting data from our seminal white paper, Pharmaprojects Pharma R&D Annual Review 2017. Over the past 25 years, the pharma R&D sector has seen many twists and turns.

Included with your purchase, our white paper looks at developments in a year that saw some new players make the big time, while others hit skid row after one too many negative (clinical) reviews. Sourced from Pharmaprojects, the industry’s most trusted clinical drug development database, the information included in this datapack covers multiple views of the R&D pipeline by company, development phase, therapy area, and more, allowing you to perform your own analysis and dive deeper into the underlying data.

Disease Group Covered:

  • Allergy
  • Autoimmune/immunology
  • Cardiovascular
  • Dermatology
  • Endocrine
  • Gastroenterology (non inflammatory bowel disease)
  • Hematology
  • Infectious disease
  • Metabolic
  • Neurology
  • Not Specified
  • Obstetrics/Gynecology
  • Oncology
  • Ophthalmology
  • Orthopedics
  • Psychiatry
  • Renal
  • Respiratory
  • Rheumatology (non autoimmune)
  • Urology
Note: Product cover images may vary from those shown
2 of 3

List of Figures:
Figure 1 Total R&D Pipeline Size by Year 2001-2017
Figure 2 Pipeline by Development Phase
Figure 3 Clinical Phase Trends 2007-2017
Figure 4 Distribution of Likelihood of Approval Ratings for Pipeline Drugs in Phase II to Pre-registration
Figure 5 Total Number of Companies with Active Pipelines 2001-2017
Figure 6 Distribution of R&D Companies by HQ Country/Region 2016 and 2017
Figure 7 The R&D Pipeline by Therapy Group
Figure 8 Biological vs Non-biological Drugs as a Percentage of the Pipeline 1995-2017
Figure 9 Pipeline by Delivery Route 2016 & 2017
Figure 10 Number of New Drug Protein Targets Identified by Pharmaprojects by Year
Figure 11 Rise in Numbers of Drugs Receiving Orphan Drug Status or an Expedited Review Designation 2013-2016

List of Tables:
Table 1 Top 25 Pharma Companies by Size of Pipeline
Table 2 Top 25 Therapeutic Categories
Table 3 Top 25 Diseases/Indications
Table 4 Top 25 Origins of Pipeline Drugs
Table 5 Top 25 Mechanisms of Action (Pharmacologies)
Table 6 Top 25 Drug Protein Targets

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown